Our findings demonstrate that mTOR kinase inhibitors from three successive generations, particularly when used in combination with MEK1/2 inhibition, significantly reduce melanoma cell invasiveness and downregulate metalloproteinases MMP-2 and MMP-9. The gene discussed is MMP2; the disease is melanoma.